{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:43Z","timestamp":1785117583623,"version":"3.55.0"},"reference-count":54,"publisher":"IMR Press","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Levosimendan is a calcium-sensitizing inodilator that has attracted renewed attention for a potential role in the management of cardiogenic shock (CS). The pharmacological profile of levosimendan differs markedly from that of adrenergic inotropes: levosimendan augments contractile force without increasing intracellular calcium or myocardial oxygen demand and, through activation of ATP-sensitive (KATP) potassium channels, produces systemic and coronary vasodilation. Experimental and clinical data also suggest additional protective effects, including modulation of inflammatory pathways, anti-apoptotic activity, and improved mitochondrial function. Although these mechanisms translate into consistent hemodynamic improvement across several studies, large, randomized trials have not demonstrated a consistent survival advantage, likely due to differences in patient selection, treatment timing, and concomitant therapies. Nevertheless, certain clinical groups, such as patients who fail to respond to catecholamines, individuals on chronic \u03b2-blockers, and selected perioperative or mechanically supported patients, appear more likely to benefit. Therefore, current guidance favors an individualized rather than universal approach to levosimendan use. Several ongoing investigations, including trials in extracorporeal membrane oxygenation (ECMO)-supported patients and those with septic cardiomyopathy, may help clarify the optimal indications and timing for levosimendan use. This review integrates mechanistic, clinical, and safety data to identify patient profiles most suited to levosimendan therapy and to outline areas where further study is needed.<\/jats:p>","DOI":"10.31083\/rcm47062","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:28:22Z","timestamp":1785115702000},"source":"Crossref","is-referenced-by-count":0,"title":["Levosimendan in Cardiogenic Shock: A Review of Mechanisms, Clinical Evidence, and Therapeutic Use"],"prefix":"10.31083","volume":"27","author":[{"given":"Stefano","family":"Salvini","sequence":"first","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Trivelloni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Monaco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Samet","family":"Bouhaik","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insaf","family":"Chouarfia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iheb","family":"Guefrachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Bencharef","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounia","family":"Sedrati","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charaf","family":"Mouhand","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bottigliero","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier G\u00e9n\u00e9ral Victor Jousselin de Dreux, 28100 Dreux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal. 2019; 40: 2671\u20132683.","DOI":"10.1093\/eurheartj\/ehz363"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chien SC, Wang CA, Liu HY, Lin CF, Huang CY, Chien LN. Comparison of the prognosis among in-hospital survivors of cardiogenic shock based on etiology: AMI and Non-AMI. Annals of Intensive Care. 2024; 14: 74.","DOI":"10.1186\/s13613-024-01305-2"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units: Data From the Critical Care Cardiology Trials Network Registry. Circulation. Cardiovascular Quality and Outcomes. 2019; 12: e005618.","DOI":"10.1161\/CIRCOUTCOMES.119.005618"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Waksman R, Pahuja M, van Diepen S, Proudfoot AG, Morrow D, Spitzer E, et al. Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC). Circulation. 2023; 148: 1113\u20131126.","DOI":"10.1161\/CIRCULATIONAHA.123.064527"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Naidu SS, Baran DA, Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, et al. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. Journal of the American College of Cardiology. 2022; 79: 933\u2013946.","DOI":"10.1016\/j.jacc.2022.01.018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Jentzer JC, Van Diepen S, Patel PC, Henry TD, Morrow DA, Baran DA, et al. Serial Assessment of Shock Severity in Cardiac Intensive Care Unit Patients. Journal of the American Heart Association. 2023; 12: e032748.","DOI":"10.1161\/JAHA.123.032748"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal. Acute Cardiovascular Care. 2020; 9: 183\u2013197.","DOI":"10.1177\/2048872619894254"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017; 136: e232\u2013e268.","DOI":"10.1161\/CIR.0000000000000525"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Pollesello P, Ovaska M, Kaivolai J, Tilgmann C, Lundstrom K, Kalkkinen N, et al. Binding of a New Ca2+ Sensitizer, Levosimendan, to Recombinant Human Cardiac Troponin C. The Journal of Biological Chemistry. 1994; 269: 28584\u201328590.","DOI":"10.1016\/S0021-9258(19)61945-9"},{"key":"ref11","unstructured":"Papp Z, \u00c9des I, Fruhwald S, De Hert SG, Salmenper\u00e4 M, Leppikangas H, et al. Levosimendan: Molecular mechanisms and clinical implications. Pharmacology & Therapeutics. 2012; 136: 26\u201357."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology. 2020; 76: 4\u201322.","DOI":"10.1097\/FJC.0000000000000859"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Tamargo J, Caballero R, G\u00f3mez R, Barana A, Amor\u00f3s I, Delp\u00f3n E. Investigational positive inotropic agents for acute heart failure. Cardiovascular & Hematological Disorders Drug Targets. 2009; 9: 193\u2013205.","DOI":"10.2174\/187152909789007070"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bistola V, Arfaras-Melainis A, Polyzogopoulou E, Ikonomidis I, Parissis J. Inotropes in acute heart failure: from guidelines to practical use. Cardiac Failure Review. 2019; 5: 133\u2013139.","DOI":"10.15420\/cfr.2019.11.1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and current use of levosimendan in the treatment of heart failure: filling the gap. Drug Design Development and Therapy. 2021; 15: 3391\u20133409.","DOI":"10.2147\/DDDT.S295214"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Gong B, Li Z, Yew KW, Ong HY, Yang J, Wang Y, et al. Levosimendan in patients with acute heart failure: a meta-analysis of randomized controlled trials. American Journal of Cardiovascular Drugs. 2015; 15: 87\u201398.","DOI":"10.1007\/s40256-014-0104-6"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. Journal of Clinical Pharmacy and Therapeutics. 2013; 38: 341\u2013349.","DOI":"10.1111\/jcpt.12067"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. Journal of the American College of Cardiology. 2000; 36: 1903\u20131912.","DOI":"10.1016\/s0735-1097(00)00961-x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Pan J, Yang YM, Zhu JY, Lu YQ. Multiorgan Drug Action of Levosimendan in Critical Illnesses. BioMed Research International. 2019; 2019: 9731467.","DOI":"10.1155\/2019\/9731467"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zangrillo A, Alvaro G, Belletti A, Pisano A, Brazzi L, Calabr\u00f2 MG, et al. Effect of Levosimendan on Renal Outcome in Cardiac Surgery Patients With Chronic Kidney Disease and Perioperative Cardiovascular Dysfunction: A Substudy of a Multicenter Randomized Trial. Journal of Cardiothoracic and Vascular Anesthesia. 2018; 32: 2152\u20132159.","DOI":"10.1053\/j.jvca.2018.02.039"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Silvetti S, Pollesello P, Belletti A. Repeated Levosimendan Infusions in the Management of Advanced Heart Failure: Review of the Evidence and Meta-analysis of the Effect on Mortality. Journal of Cardiovascular Pharmacology. 2024; 83: 144\u2013157.","DOI":"10.1097\/FJC.0000000000001506"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Heringlake M, Alvarez J, Bettex D, Bouchez S, Fruhwald S, Girardis M, et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Review of Cardiovascular Therapy. 2021; 19: 325\u2013335.","DOI":"10.1080\/14779072.2021.1905520"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Bhatt AS, Berg DD, Bohula EA, Alviar CL, Baird-Zars VM, Barnett CF, et al. De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. Journal of Cardiac Failure. 2021; 27: 1073\u20131081.","DOI":"10.1016\/j.cardfail.2021.08.014"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Farmakis D, Agostoni P, Baholli L, Bautin A, Comin-Colet J, Crespo-Leiro MG, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology. 2019; 297: 83\u201390.","DOI":"10.1016\/j.ijcard.2019.09.005"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Long YX, Cui DY, Kuang X, Hu Y, Hu S, Wang CP, et al. Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials. Expert Opinion on Drug Safety. 2021; 20: 1411\u20131420.","DOI":"10.1080\/14740338.2021.1951700"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. Journal of Cardiovascular Pharmacology. 2004; 43: 555\u2013561.","DOI":"10.1097\/00005344-200404000-00011"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Mishra A, Kumar B, Dutta V, Arya VK, Mishra AK. Comparative Effect of Levosimendan and Milrinone in Cardiac Surgery Patients With Pulmonary Hypertension and Left Ventricular Dysfunction. Journal of Cardiothoracic and Vascular Anesthesia. 2016; 30: 639\u2013646.","DOI":"10.1053\/j.jvca.2016.01.015"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Cui X, Wang Z, Dong X, Cheng Z, Zhang L, Mu Y, et al. Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction. Journal of Cardiovascular Pharmacology. 2022; 79: 781\u2013790.","DOI":"10.1097\/FJC.0000000000001255"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Quintero-Altare A, Fl\u00f3rez-Navas C, Robayo-Amortegui H, Rojas-Arrieta M, Tuta-Quintero E, Bastidas-Goyes A, et al. Boosting the Beat: A Critical Showdown of Levosimendan and Milrinone in Surgical and Non-Surgical Scenarios: A Narrative Review. Journal of Cardiovascular Pharmacology and Therapeutics. 2024; 29: 10742484241276431.","DOI":"10.1177\/10742484241276431"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297: 1883\u20131891.","DOI":"10.1001\/jama.297.17.1883"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Lannemyr L, Ricksten SE, Rundqvist B, Andersson B, Bartfay SE, Ljungman C, et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double-Blind Controlled Trial. Journal of the American Heart Association. 2018; 7: e008455.","DOI":"10.1161\/JAHA.117.008455"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"John B, Babu M, Shaji S, Abraham S, Abdullakutty J. Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function. Indian Heart Journal. 2021; 73: 372\u2013375.","DOI":"10.1016\/j.ihj.2021.02.010"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sanfilippo F, La Via L, Merola F, Astuto M. Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered. Cardiology Journal. 2021; 28: 798\u2013799.","DOI":"10.5603\/CJ.a2021.0078"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Feng F, Chen Y, Li M, Yuan JJ, Chang XN, Dong CM. Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis. Chinese Medical Journal. 2019; 132: 1212\u20131217.","DOI":"10.1097\/CM9.0000000000000197"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Liao X, Qian L, Zhang S, Chen X, Lei J. Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock. Journal of Healthcare Engineering. 2020; 2020: 8862256.","DOI":"10.1155\/2020\/8862256"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, et al. Treatments targeting inotropy: a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Heart Journal. 2019; 40: 3626\u20133644.","DOI":"10.1093\/eurheartj\/ehy600"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Packer M, Colucci WS, Fisher L, Massie BM, Teerlink JR, Young JB, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013; 1: 103\u2013111","DOI":"10.1016\/j.jchf.2012.12.004"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International Journal of Cardiology. 2010; 138: 281\u2013289.","DOI":"10.1016\/j.ijcard.2008.08.020"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. The New England Journal of Medicine. 2017; 376: 2032\u20132042.","DOI":"10.1056\/NEJMoa1616218"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. The New England Journal of Medicine. 2017; 376: 2021\u20132031.","DOI":"10.1056\/NEJMoa1616325"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Zhou C, Gong J, Chen D, Wang W, Liu M, Liu B. Levosimendan for Prevention of Acute Kidney Injury After Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. American Journal of Kidney Diseases. 2016; 67: 408\u2013416.","DOI":"10.1053\/j.ajkd.2015.09.015"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Guarracino F, Heringlake M, Cholley B, Bettex D, Bouchez S, Lomivorotov VV, et al. Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. Journal of Cardiovascular Pharmacology. 2018; 71: 1\u20139.","DOI":"10.1097\/FJC.0000000000000551"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"van Diepen S, Mehta RH, Leimberger JD, Goodman SG, Fremes S, Jankowich R, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. The Journal of Thoracic and Cardiovascular Surgery. 2020; 159: 2302\u20132309.","DOI":"10.1016\/j.jtcvs.2019.06.020"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Chen WC, Lin MH, Chen CL, Chen YC, Chen CY, Lin YC, et al. Comprehensive Comparisons among Inotropic Agents on Mortality and Risk of Renal Dysfunction in Patients Who Underwent Cardiac Surgery: A Network Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2021; 10: 1032.","DOI":"10.3390\/jcm10051032"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Guarracino F, Zima E, Pollesello P, Masip J. Short-term treatments for acute cardiac care: inotropes and inodilators. European Heart Journal Supplements. 2020; 22: D3\u2013D11.","DOI":"10.1093\/eurheartj\/suaa090"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Ellouze O, Soudry Faure A, Radhouani M, Abou-Arab O, Besnier E, Moussa M, et al. Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial. ESC Heart Failure. 2021; 8: 3339\u20133347.","DOI":"10.1002\/ehf2.13427"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Combes A, Saura O, Nesseler N, Lebbah S, Rozec B, Levy B, et al. Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. JAMA. 2026; 335: 60\u201369.","DOI":"10.1001\/jama.2025.19843"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Paulo N, Kimmoun A, Hajage D, Hubert P, Levy D, Pineton de Chambrun M, et al. Does Levosimendan hasten veno-arterial ECMO weaning? A propensity score matching analysis. Annals of Intensive Care. 2025; 15: 48.","DOI":"10.1186\/s13613-025-01457-9"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"M\u00f8ller JE, Sionis A, Aissaoui N, Ariza A, B\u011blohl\u00e1vek J, De Backer D, et al. Step by step daily management of short-term mechanical circulatory support for cardiogenic shock in adults in the intensive cardiac care unit: a clinical consensus statement of the Association for Acute CardioVascular Care of the European Society of Cardiology SC, the European Society of Intensive Care Medicine, the European branch of the Extracorporeal Life Support Organization, and the European Association for Cardio-Thoracic Surgery. European Heart Journal. Acute Cardiovascular Care. 2023; 12: 475\u2013485.","DOI":"10.1093\/ehjacc\/zuad064"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Wang YH, Chen JL, Tsai CS, Tsai YT, Lin CY, Ke HY, et al. Effects of Levosimendan on Systemic Perfusion in Patients with Low Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Score: Experience from a Single Center in Taiwan. Acta Cardiologica Sinica. 2021; 37: 512\u2013521.","DOI":"10.6515\/ACS.202109_37(5).20210310B"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Massol J, Simon-Tillaux N, Tohme J, Hariri G, Dureau P, Duceau B, et al. Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data. Critical Care. 2023; 27: 51.","DOI":"10.1186\/s13054-023-04328-6"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Fox H, Gummert JF, Sommer P, Knabbe C, Sohns C. Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report. Cardiology Journal. 2022; 29: 157\u2013159.","DOI":"10.5603\/CJ.a2021.0119"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Susilo H, Aldian FM, Wungu CDK, Alsagaff MY, Sutanto H, Multazam CECZ. Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review. European Cardiology Review. 2024; 19: e21.","DOI":"10.15420\/ecr.2024.16"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Kocabeyoglu SS, Kervan U, Sert DE, Karahan M, Aygun E, Beyazal OF, et al. Optimization with levosimendan improves outcomes after left ventricular assist device implantation. European Journal of Cardio-Thoracic Surgery. 2020; 57: 176\u2013182.","DOI":"10.1093\/ejcts\/ezz159"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/5\/10.31083\/RCM47062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:29:20Z","timestamp":1785115760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/5\/10.31083\/RCM47062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02862-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm47062","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"47062"}}